fbrewnd.info

You may be surprised to learn that nutritional supplements vary significantly in quality and effectiveness. Even products with the same brand name may have very different results varying from some positive effects to no effect or, in some cases, harmful effects.Formulations are often thrown together using ingredients which have had lots of media attention, in an attempt to fill a demand and make some money at your expense. No thought goes into what nutrients are combined with what minerals or what enzymes.The fact is, you can’t simply cram a bunch of popular, high profile nutrients together in a pill and expect them to be of any benefit to your health. Without proper formulation, supplements will not have the nutritional cofactors and phytonutrients your body requires. As a result, your body will not recognize and absorb the nutrients and they will (hopefully) pass through your system with no benefit. I say hopefully because, in some instances, they will actually do more harm than good.Now you are thinking, “How can nutritional supplements harm me?” Read on and I will explain.To ensure nutrition is delivered to the cells of your body, it is necessary that each nutritional supplement contains a formulation specifically matched with quality whole food ingredients. In other words, each product contains the necessary enzymes, minerals and co-factors in the exact balance that is found in nature.This “delivery system” should:

Deliver the nutrients to the blood stream quickly,

Ensure the highest absorption possible,

Provide minerals and co-factors which promote optimum enzyme activity,

Guarantee that the nutrients are delivered to the cells of your body and

Support your body’s natural absorption processes.
What happens if the supplements I take do not have a delivery system?Coordinated enzymes and minerals must be present for nutrients to reach the cells of your body. As a result, certain minerals and co-factors are required in order for enzyme activity to occur. If they are not available, enzyme activity “robs” your body’s nutrient stores to make up the shortfall. Over a long period of time your health may suffer and in some cases, the effects may be irreversible.What is meant by the term “cellular nutrition”? Do the cells in my body actually eat? Yes! In a manner of speaking, they do eat.In 1942, the nutritionist Victor Lindlahr published “You Are What You Eat: how to win and keep health with diet”. (The phrase is actually much older but it appears that this publication is what brought it into the public consciousness) Since that time we have been obsessed with the notion that if we eat a well balanced diet we will ensure good heath and vitality.However, in recent history, nutritionists have discovered that it is not necessarily the nutrition we consume but the nutrition that is delivered to and absorbed by our cells that determines our health. This is why it’s important to ensure that each cell not only receives the nutrients it needs but receives it in a format that is recognizable and easy to absorb (eat).What can stop supplements from reaching my cells?If a nutritional supplement does not have the right molecular structure they may not be able to make the journey through the stomach and into the blood stream.Sometimes this can be a good thing. “Vitamin C from ascorbic acid” (have you seen this phrase on labels?), for example, contains only a fraction of the whole vitamin C. If this fractionated nutrient were to get through, the rest of the co-factors would have to be obtained so that it can be utilized. This “robs” your body of vital reserves and may result in unfavorable health conditions in the future.What happens when vitamins and minerals are not absorbed?When vitamins, minerals and herbs are not absorbed they can get into areas of your body where their presence will cause problems. Iron in your liver, for example, can cause liver damage because your body is unable to dispose of it. Other vitamins and minerals, especially vitamins A, D, E and K can cause similar problems in other organs.So, to answer the question posed at the beginning of this article…… Are Nutritional Supplements a Waste of Money?They can be if they do not include a strategy that ensures Cellular Nutrition Guaranteed but ….If your supplements incorporate a good strategy for Cellular Delivery along with:

100% all-natural raw materials that Obey the Laws of Nature,

Nutrition that fulfill your body’s needs not market trends,

A holistic formulation that does not interrupt or interfere with the harmony and balance of the natural functioning of your body and

Nutrition from whole food complexes (example: whole food vitamin) not fractionated or synthetic sources,
You will be surprised at the fantastic results you can achieve.”Guaranteed Cellular Delivery” – What a concept!

Your stocks to watch for the week ahead are Cheniere Energy (LNG), S&P 500 biotech giant Vertex Pharmaceuticals (VRTX), Cardinal Health (CAH), Steel Dynamics (STLD) and Genuine Parts (GPC).

X
While the market remains in correction, with analysts and investors wary of an economic downturn, these five stocks are worth adding to watchlists. S&P 500 medical giants Vertex and Cardinal Health have been holding up, as health-care related plays tend to do well in down markets.

Steel Dynamics and Genuine Parts are both coming off strong earnings as both the steel and auto parts industries report optimistic outlooks. Meanwhile, Cheniere Energy saw sales boom in the second quarter as demand in Europe for natural gas continues to grow.

Major indexes have been making rally attempts with the Dow Jones and S&P 500 testing weekly support on Friday. With market uncertainty, investors should be ready for follow-through day breakouts and keep an eye on these stocks.

Cheniere Energy, Cardinal Health and VRTX stock are all on IBD Leaderboard.

Cheniere Energy Stock
LNG shares rose 1.1% to 175.79 during Friday’s market trading. On the week, the stock advanced 3.1%, not from highs, bouncing from its 21-day and 10-week lines earlier in the week.

Cheniere Energy has been consolidating since mid-September, but needs another week to forge a proper base, with a potential 182.72 buy point formed on Aug. 10.

Houston-based Cheniere Energy was IBD Stock Of The Day on Thursday, as the largest U.S. producer of liquefied natural gas eyes strong demand in Europe.

Even though natural gas prices are plunging in the U.S. and Europe, investors still see strong LNG demand for Cheniere and others.

The U.K. government confirmed last week that it is in talks for an LNG purchase agreement with a number of companies, including Cheniere.

In the first half of 2021, less than 40% of Cheniere’s cargoes of LNG landed in Europe. That jumped to more than 70% through this year’s second quarter, even as the company ramped up new export capacity. The urgency of Europe’s natural gas shortage only intensified last month. That is when an explosion disabled the Nord Stream 1 pipeline from Russia that had once supplied 40% of the European Union’s natural gas.

In Q2, sales increased 165% to $8 billion and LNG earned $2.90 per share, up from a net loss of $1.30 per share in Q2 2021. The company will report Q3 earnings Nov. 3, with investors seeing booming profits for the next few quarters.

Cheniere Energy has a Composite Rating of 84. It has a 98 Relative Strength Rating, an exclusive IBD Stock Checkup gauge for share price movement with a 1 to 99 score. The rating shows how a stock’s performance over the last 52 weeks holds up against all the other stocks in IBD’s database. The EPS rating is 41.

Vertex Stock
VRTX stock jumped 3.4% to 300 on Friday, rebounding from a test of its 50-day moving average. Shares climbed 2.2% for the week. Vertex stock has formed a tight flat base with an official buy point of 306.05, according to MarketSmith analysis.

The stock has remained consistent over recent weeks, while the relative strength line has trended higher. The RS line tracks a stock’s performance vs. the S&P 500 index.

Vertex Q3 earnings are on due Oct. 27. Analysts see EPS edging up 1% to $3.61 per share with sales increasing 16% to $2.2 billion, according to FactSet.

The Boston-based global biotech company dominates the cystic fibrosis treatment market. Vertex also has other products in late-stage clinical development that target sickle cell disease, Type 1 diabetes and certain genetically caused kidney diseases. That includes a gene-editing partnership with Crispr Therapeutics (CRSP).

In early August, Vertex reported better-than-expected second-quarter results and raised full-year sales targets.

S&P 500 stock Vertex ranks second in the Medical-Biomed/Biotech industry group. VRTX has a 99 Composite Rating. Its Relative Strength Rating is 94 and its EPS Rating is 99.

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

Cardinal Health Stock
CAH stock advanced 3.2% to 73.03 Friday, clearing a 71.22 buy point from a shallow cup-with-handle base and hitting a record high. But volume was light on the breakout. CAH stock leapt 7.3% for the week.

Cardinal Health stock’s relative strength line has also been trending up for months.

The cup-with-handle base is part of a base-on-base pattern, forming just above a cup base cleared on Aug. 11.

Cardinal Health, based in Dublin, Ohio, offers a wide assortment of health care services and medical supplies to hospitals, labs, pharmacies and long-term care facilities. The company reports that it serves around 90% of hospitals and 60,000 pharmacies in the U.S.

S&P 500 stock Cardinal Health will report Q1 2023 earnings on Nov. 4. Analysts forecast earnings falling 26% to 96 cents per share. Sales are expected to increase 10% to $48.3 billion, according to FactSet.

Cardinal Health stock ranks first in the Medical-Wholesale Drug/Supplies industry group, ahead of McKesson (MCK), which is also showing positive action. CAH stock has a 94 Composite Rating out of 99. It has a 97 Relative Strength Rating and an EPS rating of 73.

Steel Dynamics Stock
STLD shares shot up 8.5% to 92.92 on Friday and soared 19% on the week, coming off a Steel Dynamics earnings beat Wednesday night.

Shares blasted above an 88.72 consolidation buy point Friday after clearing a trendline Thursday. STLD stock is 17% above its 50-day line, definitely extended from that key average.

Steel Dynamics’ latest consolidation could be seen as part of a larger base going back six months.

Steel Dynamics topped Q3 earnings views with EPS rising 10% to $5.46 while revenue grew 11% to $5.65 billion. The steel producer’s outlook is optimistic despite weaker flat rolled steel pricing. STLD reports its order activity and backlogs remain solid.

The Fort Wayne, Indiana-based company is among the largest producers of carbon steel products in the U.S. It engages in metal recycling operations along with steel fabrication and produces myriad steel products.

How Millett Grew Steel Dynamics From A Three Employee Business

STLD stock ranks first in the Steel-Producers industry group. STLD stock has a 96 Composite Rating out of 99. It has a 90 Relative Strength Rating, an exclusive IBD Stock Checkup gauge for share-price movement that tops at 99. The rating shows how a stock’s performance over the last 52 weeks holds up against all the other stocks in IBD’s database. The EPS rating is 98.

Genuine Parts Stock
GPC stock gained 2.8% to 162.35 Friday after the company topped earnings views with its Q3 results on Thursday. For the week GPC advanced 5.1% as the stock held its 50-day line and is in a flat base.

GPC has an official 165.09 flat-base buy point after a three-week rally, according to MarketSmith analysis.

The relative strength line for Genuine Parts stock has rallied sharply to highs over the past several months.

On Thursday, the Atlanta-based auto parts company raised its full-year guidance on growth across its automotive and industrial sales.

Genuine Parts earnings per share advanced 19% to $2.23 and revenue grew 18% to $5.675 billion in Q3. GPC’s full-year guidance is now calling for EPS of $8.05-$8.15, up from $7.80-$7.95. The company now forecasts revenue growth of 15%-16%, up from the earlier 12%-14%.

During the Covid pandemic, supply chain constraints caused a major upheaval in the auto industry, sending prices for new and used cars to record levels. This has made consumers more likely to hang on to their existing vehicles for longer, driving mileage higher and boosting demand for auto replacement parts.

Fellow auto stocks O’Reilly Auto Parts (ORLY) and AutoZone (AZO) have also rallied near buy points amid the struggling market. O’Reilly reports on Oct. 26.

IBD ranks Genuine Parts first in the Retail/Wholesale-Auto Parts industry group. GPC stock has a 96 Composite Rating. Its Relative Strength Rating is 94 and it has an EPS Rating of 89.